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Abstract Purpose: The objective
of this study was to demonstrate the
safety and performance of a unique
extracorporeal carbon dioxide
removal system (Hemolung, ALung
Technologies, Pittsburgh, PA) which
incorporates active mixing to improve
gas exchange efficiency, reduce
exposure of blood to the circuit, and
provide partial respiratory support at
dialysis-like settings. Methods: An
animal study was conducted using
eight domestic crossbred sheep,
6–18 months of age and 49–115 kg in
weight. The sheep were sedated and
intubated, and a 15.5-Fr dual lumen
catheter was inserted into the right
jugular vein. The catheter was con-
nected to the extracorporeal circuit
primed with heparinized saline, and
flow immediately initiated. The ani-
mals were then awakened and
encouraged to stand. The animals
were supported in a stanchion and
monitored around the clock. Antico-
agulation was maintained with
heparin to achieve an aPTT of
46–70 s. Results: Measurements
included blood flow rate through the
device, carbon dioxide exchange rate,
pump speed and sweep gas flow rate.
Safety and biocompatibility mea-
surements included but were not
limited to plasma-free hemoglobin,
hematocrit, white blood cell count,
platelet count and fibrinogen. The
Hemolung removed clinically signif-
icant amounts of carbon dioxide,
more than 50 ml/min, at low blood
flows of 350–450 ml/min, with mini-
mal adverse effects.
Conclusions: The results of 8-day
trials in awake and standing sheep
supported by the Hemolung demon-
strated that this device can
consistently achieve clinically rele-
vant levels of carbon dioxide removal
without failure and without signifi-
cant risk of adverse reactions.
Keywords Chronic obstructive
pulmonary disease (COPD) 
Acute respiratory distress syndrome
(ARDS)  Extracorporeal membrane
oxygenation (ECMO) 
Extracorporeal life support (ECLS) 
Ventilation  Gas exchange
Introduction
Extracorporeal carbon dioxide removal (ECCO2R), or
‘‘partial ECMO’’, is a form of extracorporeal life support
therapy which has received renewed interest as an adjunct
or alternative to invasive mechanical ventilatory support
for patients suffering from reversible acute hypercapnic
respiratory lung failure [1]. A clinical need for alternative
respiratory support therapies providing carbon dioxide
(CO2) removal exists for both patients experiencing acute
exacerbation of chronic obstructive pulmonary disorder
(COPD) as well as those with acute respiratory distress
syndrome. In acute exacerbation of COPD, patients who
do not respond effectively to drug therapy exhibit
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increasing respiratory acidosis and hypercapnia, while
remaining normoxic due to supplemental oxygen [2].
Despite the advent and effectiveness of non-invasive
ventilation, invasive mechanical ventilation is still
required by 26 % to 54 % of patients [3, 4]. The prog-
nosis for COPD patients requiring invasive mechanical
ventilation for ventilatory failure is poor, with hospital
survival ranging from 76 % to as low as 31 % [5–9]. In
respiratory distress syndrome, lung protective ventilation
using lower tidal volumes may be complicated by sig-
nificant CO2 retention, which can lead to arrhythmias and
severe dyspnea [10].
Advances in gas exchanger, pump and catheter tech-
nologies, in conjunction with the recognized utility of lower
flow rate venovenous support modes, have reduced the risks
associated with extracorporeal life support, thus opening
the door for consideration of its use in earlier stages of acute
lung failure [11–14]. The Hemolung respiratory assist
system (ALung Technologies, Pittsburgh, PA) is a novel
artificial lung device which provides extracorporeal CO2
removal with a cannula and at blood flow rates similar to
those used in continuous renal replacement therapy. This
device was designed to provide partial respiratory support
through a single 15.5-Fr venovenous catheter at blood flow
rates of 350–450 ml/min. The system is unique in that it
uses active mixing of the blood adjacent to the hollow fiber
membranes (HFM) to increase its gas exchange efficiency,
allowing a smaller fiber surface area and reduced flow rates.
The levels of oxygenation provided are secondary and
recognized to be subtherapeutic.
The purpose of the in vivo study presented in this paper
was to demonstrate the safety and performance of the
Hemolung for extracorporeal CO2 removal in standing,
awake sheep over an 8-day period. The design and method-
ology of this study was developed to support regulatory
approval for clinical testing of the Hemolung. The objective
in using healthy sheep was both to maximize the consistency
in the length of the study, and to allow evaluation of safety
independent of risks associated with disease states or
mechanical ventilation. Based on its design and performance
in vitro, it was hypothesized that the Hemolung could provide
consistent CO2 removal exceeding 50 ml/min at an arterial
CO2 partial pressure (PCO2) of 45 mmHg and at blood flow
rates in the range 350–450 ml/min. It was further hypothe-
sized that this level of CO2 exchange could be provided
without failure or clinically significant adverse reaction in
healthy awake sheep for an extended period of 8 days.
Materials and methods
Animal selection, preparation and baseline assessment
This study was approved by the University of Pittsburgh
Institutional Animal Care and Use Committee, and the
care and handling of the animals were conducted in
accordance with the standards set forth in the USDA
Animal Welfare Act and in the current guide for the care
and use of laboratory animals prepared by the Institute of
Laboratory Animal Resources, National Academy of
Sciences. Eight Dorset crossbred sheep weighing 49–115
kg were used for the study. Prior to surgery, the animals
were premedicated with atropine (0.05 mg/kg, intramus-
cular) followed by initial anesthetic induction with
ketamine hydrochloric acid (30 mg/kg, intramuscular).
Endotracheal intubation was achieved under direct visu-
alization. A surgical plane of anesthesia was achieved
using isoflurane (1–3 % to effect) followed by the place-
ment of an oral–gastric tube for abdominal decompression.
Monitoring lines were placed in the left external jugular
vein and carotid artery. Baseline assessment included
arterial pressure, heart rate, blood gases, blood chemistry,
complete blood count, activated partial thromboplastin
time (aPTT), and plasma-free hemoglobin (PfHb).
Description of Hemolung respiratory assist system
The primary component of the Hemolung system is a
cartridge which houses a cylindrical bundle of siloxane
and heparin-coated HFM positioned around a spinning
core which simultaneously drives blood flow (centrifu-
gally) through the cartridge and CO2 removal from the
blood into the oxygen sweep gas flowing under negative
pressure through the fiber lumens (Fig. 1b). The total fiber
surface area of the gas exchange cartridge is 0.59 m2. The
cartridge is magnetically mated to and driven by an
integrated control console (Fig. 1a). Device performance
is controlled from the console monitor using two
parameters: rotational speed of the cartridge core (rpm)
and sweep gas flow (l/min) through the fibers. The system
was interfaced with the sheep through a custom dual
lumen 15.5-Fr catheter (Fig. 1c) similar to a dialysis
catheter, but with lower flow resistance and greater kink
resistance. The volume of the circuit is 280 ml and is
primed with sterile 0.9 % sodium chloride containing one
unit of heparin per milliliter immediately prior to the
procedure.
Surgical procedure
Following placement of monitoring lines and baseline
assessments, the animals were rotated to a left lateral
decubitus position. The Hemolung catheter was inserted
using a percutaneous Seldinger technique [15]. Following
guide wire placement and vessel dilation, a heparin bolus
(80 U/kg) was administered. The Hemolung catheter was
then advanced into the vasculature under the guidance of
fluoroscopy. The tip of the catheter was advanced to the
junction of the right atrium and the superior vena cava.
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After confirming position, the blood tubing was con-
nected, and extracorporeal flow through the Hemolung
circuit immediately initiated. The catheter was secured
to the skin with sutures. Hemolung gas flow was set to
8 l/min and the rotational speed was adjusted to obtain a
blood flow of approximately 400 ml/min. A systemic
intravenous (IV) heparin drip (100 U heparin per milli-
liter normal saline) was used to maintain aPTT levels in
the range 46–70 s (1.5–2.3 times baseline) during the
chronic phase of the trial.
Animal recovery, maintenance, monitoring
and measurements
After securing the catheter and initiating Hemolung cir-
culation, anesthesia was discontinued and the animal was
extubated. The animal was then transported to the ICU
where it was cared for in individual stanchions. Vital
signs were monitored hourly over the course of the study,
including heart rate, arterial blood pressure, output, and
intake. In addition, all animals received prophylactic
antibiotic (cephalexin, 3 g/day IV) and analgesic (flunixin
meglumine, 1 mg/kg IV twice per day for the first 3 days,
or longer as needed).
A series of pathology parameters were measured at
regular intervals to assess the health of the animal, the
performance of the Hemolung device, and the effect of
the device on the sheep. These measurements included
arterial and venous blood gases, complete blood count,
serum chemistry, coagulation parameters, PfHb, urine
samples and blood smears.
Hemolung measurements
The Hemolung cartridge and controller performance was
assessed every hour throughout the duration of each trial.
Critical measurements included CO2 removal, blood flow,
pump speed in revolutions per minute (rpm), and sweep
gas flow rate. CO2 removal from the blood into the fiber
lumens of the device occurs by diffusion across the wall
of the hollow fibers, driven by the difference in PCO2
between the blood and the gas flowing through the fibers.
Since variations in blood PCO2 values would result in
variable CO2 removal rates, critical evaluation of the CO2
exchange performance required a linear normalization of
CO2 removal. The normalized CO2 exchange rate was
calculated based on a moving average of venous PCO2,






Study termination, device removal, and necropsy
After 8 days of data collection the study was terminated.
Blood samples were obtained for a complete set of
Fig. 1 Hemolung respiratory
assist system: a controller with
cartridge magnetically
mounted; b schematic of
integral gas exchange/pump
unit; c dual lumen catheter
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terminal blood studies including blood culture. Before the
animals were euthanized they were heparinized (100 IU/kg,
IV) for anticoagulation. After flushing with heparinized
saline, the device was examined for evidence of thrombus
deposition. A complete necropsy examination of each ani-
mal was performed with the Hemolung catheter in situ.
Following explant, the catheter was rinsed with saline and
inspected for thrombus and mechanical integrity. The
luminal vascular surfaces of the animal were evaluated for
potential gross damage related to catheter placement and
operation. The organs were evaluated for pathology and
evidence of embolic injury. Particular attention was paid to
the lungs and the pulmonary arterial vasculature. Repre-
sentative samples from each of the major organs (lungs,
heart, kidneys, liver, and spleen) and the adrenal glands
were taken for histopathology.
Results
Eight healthy sheep were successfully placed on Hemolung
therapy under anesthesia, resuscitated, and monitored for up
to 8 days. The Hemolung catheter was percutaneously
inserted without incident. Recovery from anesthesia was
uneventful in all animals. Mechanically, the Hemolung
performed as intended with no bearing failures. The
Hemolung controller also performed as expected with no
loss of sweep gas flow or other failures. Six of the eight
animals remained on the device for the entire 8 days. In the
second and sixth animals, the Hemolung catheter became
dislodged causing premature cessation of treatment. No
animals died unexpectedly during the study. The following
is a summary of the major findings from the measurements
and observations collected prior to, during, and immediately
following each animal trial.
Average daily blood flow rates through the Hemolung
device are shown in Fig. 2 with corresponding average
pump speeds. The normalized CO2 removal rates for each
animal are shown in Fig. 3, which includes a table listing the
daily average venous PCO2 values. The target blood flow
rate of 350–450 ml/min was obtained at nominal pump
speeds. This flow rate successfully supported the target
minimum CO2 removal rate of 50 ml/min at a venous PCO2
of 45 mmHg without degradation in all but one animal. In
the fourth animal, which remained on Hemolung therapy for
8 days, a bleeding complication occurred on the third day
from a damaged venous monitoring catheter. Blood counts
in this animal demonstrated moderate to marked anemia due
to bleeding at the site of the venous monitoring line (left
neck, opposite side to Hemolung catheter). A blood trans-
fusion was administered on the third day. No other animals
experienced bleeding complications.
The results associated with hemocompatibility and
organ function are listed in Table 1. The statistical sig-
nificance of changes over time were evaluated using a
two-tailed heteroscedastic Student’s t test. Hemocompat-
ibility measures included hematocrit, platelet count, white
blood cell (WBC) count, fibrinogen, PfHb and total bili-
rubin. Figure 4 shows individual PfHb measurements for
each animal over the course of treatment. Kidney and
liver function were assessed using aspartate transaminase
(AST), alanine transaminase (ALT), creatinine, and urea
nitrogen (BUN). No animal showed any signs of infection
and all remained normothermic throughout treatment.
All necropsy and histopathology results were unre-
markable, with the exception of the animal which
experienced the bleeding complication. There were no
gross anatomic lesions found in any of the sheep. All
visceral organs were considered to be within normal
limits. No intimal vessel damage or vascular clots were
seen. Thrombus at the catheter insertion site was seen in
some animals. This was considered a normal finding
consistent with central venous catheterization. There was
no definitive evidence of thromboembolic injury in any of
the organs examined, including the lungs. The pulmonary
vasculature in all sheep was within normal limits with no
evidence of reactive endothelium or thrombus. At nec-
ropsy in the fourth animal which experienced the bleeding
complication at the site of the venous monitoring line, a
kink in the line at the point where it entered the vein was
observed. In this animal, there was evidence of minimal
subacute to chronic inflammation in the lung, seen as
alveolar proteinosis, type II cell hyperplasia, eosinophilic
infiltration, and pigmented macrophages. These findings
were considered to be a result of the blood transfusion.
Following explant, thrombi of various sizes were
found entrained in the bottom gap below the rotating core
of three of the eight devices. These thrombi were stable
and unable to pass through the fiber bundle, which
effectively acted as a filter, and did not affect device
performance. Varying amounts of adherent thrombus
were found on the fiber bundles, primarily at the warp
threads of the fiber mat and the potting junctions, and did
Fig. 2 Average flow rate of blood through the Hemolung circuit
(left axis) plotted with average pump motor speed (right axis)
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not appear to affect gas exchange. The spinning core
bearings were all free of any intrusion of blood.
Discussion
The primary aim of this study was to demonstrate the
safety and effective performance of the Hemolung over an
8-day period. The in vivo model of healthy awake and
standing sheep for an 8-day period was used to maximize
the ability to evaluate long-term device performance and
reliability, and to detect adverse reactions. The primary
measurements made to evaluate device performance were
the rate of CO2 removal, the rate of blood flow through
the device, and the speed of the rotating core of the fiber
bundle (other device performance measures were also
monitored and recorded). The safety of the therapy pro-
vided by the Hemolung was assessed by measurements of
animal health, including physiologic monitoring (blood
pressure, pulse, and temperature), hematology (complete
blood count), serum chemistry, coagulation studies, PfHb,
and urinalysis.
The CO2 exchange levels normalized to a venous PCO2
of 45 mmHg were not only consistent over the 8-day period
with little degradation (on average, 91 % of initial on day 8),
but exceeded the target level by as much as 40 % in all but
one animal. In animal four in which CO2 exchange levels
were in the range 42–53 ml/min (normalized), the bleeding
complication associated with a damaged venous monitoring
catheter resulted in a hematocrit drop of 15–17 % during the
first 4 days of the trial. CO2 transfer in the lung has been
shown to decline as a result of reduced hematocrit [16]. In
that study, a reduction in hematocrit from 45 % to 15 % was
associated with a 50 % reduction in CO2 exchange. This
same effect would be expected in the Hemolung and was
therefore the likely reason for the reduced CO2 removal
rates in this animal.
The target blood flow rate for the Hemolung was
350–450 ml/min, which was consistently observed in all
animals. The target blood flow rate was based on the optimal
range for achieving clinically significant levels of CO2
removal and on the goal of minimizing exposure of the blood
to the extracorporeal system. A fundamental objective in the
design process for the Hemolung device was to eliminate the
invasiveness, complexity and complications associated with
high blood flow ECMO and ECCO2R systems used in earlier
respiratory assist studies. This aim was achieved through
integration of a centrifugal pump within the gas exchanger.
The shear and secondary flow patterns set up by the spinning
core in the blood adjacent to the surface of the HFMs
increases the gas exchange efficiency allowing very low
blood flow through the device, as well as simplification of
the circuit. A reduced blood flow rate also allowed a
reduction in the catheter size needed for percutaneous access
to the circulatory system, and therefore the ability to utilize a
single venous insertion site with a smaller dual lumen
catheter, as opposed to the need for separate cannulations
Fig. 3 Normalized CO2
exchange rate achieved by the
Hemolung device in each
animal over time. The
minimum target level is shown
as 50 ml/min at a PCO2 of
45 mmHg. Average daily
venous CO2 tensions
corresponding to average daily
normalized CO2 removal rates
in each animal are tabulated
below the graph
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with larger bore catheters required in higher flow applica-
tions, which increases the risk of cannulation-associated
complications. Furthermore, the intended indications for
low flow partial respiratory support excludes patients
requiring venoarterial cannulation, which has been shown to
be associated with significantly greater mortality [17].
The hematology and organ function measurements
made to assess device safety showed changes, but there were
no trends or events which indicated significant adverse
safety concerns (Table 1). In this study, only one of the eight
animals (animal five) exceeded the 40 mg/dl PfHb threshold
for clinically significant hemolysis during the last 48 h of
the study (Fig. 4). At the time of elevated PfHb levels for
this animal, total bilirubin remained within the normal range
at 0.3 mg/dl or below, but both hemoglobin and hematocrit
fell. Necropsy and explant analysis revealed nothing sug-
gesting that mechanical, device-related hemolysis had
occurred in this animal, and pump speed remained stable,
indicating no increase in flow resistance through the circuit.
Initial increases in the liver function markers AST and ALT
were considered to not be indicative of liver damage, but
rather a result of muscle damage caused by the cannulation
procedure since both enzymes returned to normal over time,
and liver necropsy and histopathology results were normal.
The changes seen in hematocrit, in the absence of
hemolysis, were likely due to the frequent blood collec-
tions for analytic purposes (approximately 40–50 ml of
blood per day was drawn for testing) and were not
believed to have been caused by the device. Additionally,
the hematocrit showed a marked drop perioperatively,
even prior to initiation of extracorporeal circulation. It is
hypothesized that the perioperative hemodilution due to
intravenous fluids, as well as sequestration of red blood
cells in the spleen, shifts in body fluids and vasodilation

















































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4 PfHb over time in each animal. Time zero is immediately
following initiation of flow through the Hemolung device while the
animal was still under sedation
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Conclusion
The results of 8-day trials in six awake and standing sheep
supported by the Hemolung demonstrate that the Hemo-
lung can consistently achieve clinically relevant levels of
CO2 removal without failure and without significant risk
of adverse reactions. Normocapnic CO2 exchange rates of
50–70 ml/min were achieved through a venovenous 15.5-
Fr dual lumen catheter inserted percutaneously in the
right jugular vein at blood flow rates in the range
350–450 ml/min. There were no complications or diffi-
culties experienced with catheter insertion or positioning.
The system controller also performed successfully with-
out failure, and was easily monitored and operated by
veterinary technicians without substantial respiratory
support training. These results support the conclusion that
the Hemolung respiratory assist system may be a safe and
effective method of ECCO2R for partial respiratory sup-
port in patients suffering from acute hypercapnic
respiratory failure, and that progression to pilot clinical
trials in humans can be considered.
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